Lifestyle Modification in Psoriatic Patients With Fatty Liver

Study Overview
=================
Brief Summary
-----------------
Several recent reports have shown an increased prevalence of nonalcoholic fatty liver disease (NAFLD) in those with psoriasis, which may reflect the increased occurrence of metabolic syndrome in this patient population.

Detailed Description
-----------------
the recruitment of 60 fatty live men with chronic disease, psoriasis, will be classified to lifestyle modification group (foe 12 weeks, this patients will take supervised energy or diet restriction program plus their usual immunosuppressive drugs ) and control group will continue their drug program only)

Official Title
-----------------
Response of Fatty Liver to Lifestyle Modification in Psoriasis Patients

Conditions
-----------------
Psoriasis, Fatty Liver

Intervention / Treatment
-----------------
* Other: lifestyle modification
* Other: usual lifestyle


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: psoriasis obese patients with coexisting fatty liver chronic plaque psoriasis patients who will not show any change in immuno-modulating psoriasis therapies for at least five months before participation in the study. Exclusion Criteria: no metabolic syndrome no renal or cardiac or pulmonary disorders other types of psoriasis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: intervention group<br>The patients of this group will receive their usual immuno-modulating therapy plus life style modification (energy or diet restriction in addition to daily walking, 15000 steps) | Other: lifestyle modification<br>* for 12 week, the patients of this group will receive their usual immuno-modulating therapy plus life style modification (energy or diet restriction in addition to daily walking, 15000 steps)<br>|
| Active Comparator: control group<br>The participants of this group will receive their usual immuno-modulating therapy and continuing their usual diet and activities | Other: usual lifestyle<br>* the patients will receive the usual immuno-modulating therapy with continued usual diet and activities<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Psoriasis Area and Severity Index | it is an index used to measure level and severity of psoriasis | It will be measured after 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dermatology Life Quality Index | it is a questinnaire used to assess life quality in psoriasis humans | It will be measured after 12 weeks | 
| triglycerides | will measured in plasma | It will be measured after 12 weeks | 
| AST | it is plasma aspartate transaminase | It will be measured after 12 weeks | 
| ALT | it is plasma Alanine transaminase | It will be measured after 12 weeks | 
| BMI | it is body mass index | It will be measured after 12 weeks | 
| waist circumference | it will be measured at the level of umbilicus | It will be measured after 12 weeks |